| Literature DB >> 29638165 |
Alice Green1,2,3,4,5, Stephanie Defibaugh-Chavez1,2,3,4,5, Aphrodite Douris1,2,3,4,5, Danah Vetter1,2,3,4,5, Richard Atkinson6,7, Bonnie Kissler1,2,3,4,5, Allison Khroustalev8, Kis Robertson1,2,3,4,5, Yudhbir Sharma6,7, Karen Becker1,2,3,4,5, Uday Dessai1,2,3,4,5, Nisha Antoine9, Latasha Allen10, Kristin Holt1,2,3,4,5, Laura Gieraltowski11, Matthew Wise11, Colin Schwensohn11.
Abstract
On June 28, 2013, the Food Safety and Inspection Service (FSIS) was notified by the Centers for Disease Control and Prevention (CDC) of an investigation of a multistate cluster of illnesses of Salmonella enterica serovar Heidelberg. Since case-patients in the cluster reported consumption of a variety of chicken products, FSIS used a simple likelihood-based approach using traceback information to focus on intensified sampling efforts. This article describes the multiphased product sampling approach taken by FSIS when epidemiologic evidence implicated chicken products from multiple establishments operating under one corporation. The objectives of sampling were to (1) assess process control of chicken slaughter and further processing and (2) determine whether outbreak strains were present in products from these implicated establishments. As part of the sample collection process, data collected by FSIS personnel to characterize product included category (whole chicken and type of chicken parts), brand, organic or conventional product, injection with salt solutions or flavorings, and whether product was skinless or skin-on. From the period September 9, 2013, through October 31, 2014, 3164 samples were taken as part of this effort. Salmonella percent positive declined from 19.7% to 5.3% during this timeframe as a result of regulatory and company efforts. The results of intensified sampling for this outbreak investigation informed an FSIS regulatory response and corrective actions taken by the implicated establishments. The company noted that a multihurdle approach to reduce Salmonella in products was taken, including on-farm efforts such as environmental testing, depopulation of affected flocks, disinfection of affected houses, vaccination, and use of various interventions within the establishments over the course of several months.Entities:
Keywords: Salmonella; antimicrobial resistance in bacteria of animal origin; food safety; foodborne disease; poultry
Mesh:
Substances:
Year: 2018 PMID: 29638165 PMCID: PMC5865244 DOI: 10.1089/fpd.2017.2340
Source DB: PubMed Journal: Foodborne Pathog Dis ISSN: 1535-3141 Impact factor: 3.171
Sampling Plan by Phase and Establishment
| Phase I: 9/9/13–9/27/13 (3 weeks) | A, B, C, D | Chicken parts (5/day), whole/rotisserie chicken (3/day), chicken tenderloins/strips (2/day) | None |
| Phase II: 10/15/13–12/13/13 (9 weeks) | A, B, C, E, F | Chicken parts (4/day), whole/rotisserie chicken (2/day), chicken tenderloins/strips (1/day) | None |
| Phase III: 12/16/13–1/13/14 (4 weeks) | A, B, C | Chicken parts (3/day), whole/rotisserie chicken (1/day), chicken tenderloins/strips (1/day) | Preoperational environmental samples (4/day); Product surface swab (1/day) |
| Phase IV: 1/14/14–2/7/2014 (7 weeks) | A, B, C | Chicken parts (3/day), whole/rotisserie chicken (1/day), chicken tenderloins/strips (1/day) | None |
| Phase V: 3/3/14–8/8/14 (23 weeks) | A, B, C | Chicken parts (1/day) | None |
| Phase VI: 8/11/14–10/31/2014 (12 weeks) | C | Chicken parts (1/day) | None |
For establishments that did not produce tenderloins and those that did not produce whole carcasses, chicken parts were substituted.
| Salmonella | |||
|---|---|---|---|
| 5 (1.4) | 5 (100) | 0 | |
| 15 (4.2) | 14 (93.3) | 0 | |
| 3 (0.8) | 0 (0.0) | 0 | |
| 263 (72.9) | 22 (8.4) | 169 (64.3) | |
| 1 (0.2) | 1 (100.0) | 0 | |
| 3 (0.8) | 0 (0.0) | 1 (33.3) | |
| 44 (12.2) | 42 (95.4) | 1 (2.3) | |
| 3 (0.8) | 2 (66.6) | 0 | |
| 1 (0.2) | 1 (100) | 0 | |
| 1 (0.2) | 0 | 0 | |
| 1 (0.2) | 1 (100) | 0 | |
| 9 (2.5) | 6 (66.6) | 0 | |
| 12 (3.3) | 3 (25.0) | 3 (25.0) | |
| Total | 361 (100.0) | 97 (26.9) | 174 (48.2) |

Frequency of Salmonella isolation during intensified testing, according to the phase and the analyzed establishment.
Proportion of
| Phase I, | 29/40 (72.5) | 22/38 (56.4) | 22/38 (57.9) | 1/2 (50.0) | 74/118 (62.7) | ||
| Phase II, | 47/62 (75.8) | 40/61 (65.6) | 19/23 (82.6) | 106/145 (72.6) | |||
| Phase III, | 15/16 (93.8) | 10/11 (90.9) | 8/8 (100.0) | 33/35 (94.3) | |||
| Phase IV, | 8/10 (80) | 3/3 (100) | 9/10 (90) | 20/23 (87.0) | |||
| Phase V, | 2/2 (100.0) | 2/4 (50.0) | 3/4 (75.0) | 7/10 (70.0) | |||
| Phase VI, | 0/3 (0.0) | — | — | 0/3 (0.0) | |||
| Total | 101 | 77 | 61 | 1 | 240/334 (71.9) |
Limited Descriptive Findings for Chicken Products from California Establishments During Intensified Testing, Including Percent of Samples Positive for
| Salmonella | ||||||
|---|---|---|---|---|---|---|
| Organic | 36/117 (30.8) | 3.1, 2.1–4.7 | 16/36 (44.4) | 0.3, 0.1–0.5 | 25/36 (69.4) | 5/36 (13.9) |
| Conventional (nonorganic) | 296/2367 (12.5) | 223/296 (75.3) | 62/296 (20.9) | 159/296 (53.7) | ||
| Environmental samples | 0/163 (0.0) | — | — | — | ||
| Package swab samples | 0/90 (0.0) | |||||
| Sold under Company A brand label | 170/1395 (12.2) | 0.9, 0.7–1.2 | 132/170 (77.6) | 1.8, 1.1–2.9 | 28/170 (16.5) | 94/170 (55.3) |
| Sold under other retail or brand label | 162/1252 (12.9) | 107/162 (66.0) | 59/162 (36.4) | 70/162 (43.2) | ||
| Skin-on product[ | 194/1735 (11.2) | 0.7, 0.6–0.9 | 142/194 (73.2) | 1.2, 0.7–1.9 | 50/194 (25.8) | 99/194 (51.0) |
| No skin[ | 138/909 (15.2) | 97/138 (70.3) | 37/138 (26.8) | 65/138 (47.1) | ||
| Injected product (conventional only)[ | 49/428 (11.4) | 0.9, 0.6–1.2 | 36/49 (73.5) | 1.1, 0.6–2.2 | 8/49 (16.3) | 32/49 (65.3) |
| Non-injected product (conventional only)[ | 283/2216 (12.8) | 203/283 (71.7) | 79/283 (27.9) | 132/283 (46.6) |
Data on skin and flavor injection not collected for three samples.